The wire — 28 September 2026

Monday morning catches up with four rounds announced last week and not covered in the Friday or Saturday briefs — rounds that fell into the scheduling gap between the week's depth of AI-company coverage and the quiet Sunday desk. The largest by distance is from outside France: Helsinki's Kasvu Therapeutics raised a €30M Series A for a neuroplasticity drug. The three French rounds are smaller and structurally distinct from the week's agent-company cluster, but two of them share a position worth naming.

Iopole and Shadow Santé are both selling software whose primary demand driver is a regulatory mandate. Iopole sells e-invoicing infrastructure to software editors who need it because France is making e-invoicing obligatory; Shadow Santé sells environmental reporting software to hospitals that are legally required to produce annual carbon accounts. Neither company's pitch is primarily "you'll want this" — it is "you'll need this, and we make it cheaper than building it yourself." The compliance-as-distribution model concentrates demand in a way that product-led growth takes years to replicate. Whether it builds a sustainable business depends on retention after the initial deadline scramble; that question will play out in 2027. Wheelmove and Kasvu are separate strands: a wheelchair conversion kit from Hauts-de-France, and a Finnish bet that TrkB pharmacology unlocks a mass-market antidepressant without the clinical-administration ceiling that psychedelics carry.

Kasvu Therapeutics — Helsinki, €30M Series A

Kasvu Therapeutics raised €30 million in a Series A led by Hadean Ventures, with Tesi, Innovestor Life Science Fund, the Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments, and Helsinki University Funds. Founded in 2023 by Jami Mandelin (CEO) and Professor Eero Castrén (University of Helsinki), the company is advancing KTX-0141 — a first-in-class TrkB positive allosteric modulator — toward Phase 1/1b for major depressive disorder, with clinical start targeted for H2 2027. The drug amplifies BDNF-driven neuroplasticity without activating 5-HT2A receptors, removing the hallucinogenic effects and supervised-session requirement that constrain psilocybin and ketamine. Hadean's thesis: "Kasvu goes directly to TrkB, the core node of neuroplasticity, with a selective small molecule designed for at-home use." Capital funds the IND/CTA package and the Phase 1 programme.

Iopole — Hérault, €3M

Iopole raised €3 million from IRDI Capital Investissement and Sofilaro. The company operates as a Plateforme de Dématérialisation Partenaire (PDP) — a government-certified e-invoicing operator under France's mandatory B2B invoicing reform. It sells the platform white-label via API to ERP publishers and software editors rather than to end clients, who integrate it into their own products under their own brand. Stage undisclosed. The business is a race against a hard deadline: software vendors are selecting PDP partners now, before the next enforcement date, and the certification is in place. The question is whether Iopole can close enough editor partnerships before a larger incumbent absorbs the market.

Shadow Santé — Sophia Antipolis, €2.5M

Shadow Santé raised €2.5 million from Good Only Ventures, Impact Seed Ventures, Paris Business Angels, Provence Angels, Angels Santé, and Caisse d'Épargne Côte d'Azur. The company develops environmental management software for healthcare establishments, automating the carbon accounting and energy monitoring that French hospitals are required to produce under the Grenelle II framework. Stage undisclosed. The commercial framing is that the savings from identifying high-consumption areas finance the platform cost — making the transition self-funding for hospitals with constrained budgets. The broad regional angel base is a distribution signal for France's south; international expansion is in the stated plan, with no specific markets named.

Wheelmove — Hauts-de-France, €1.5M Seed

Wheelmove raised €1.5 million in a Seed from Rives Croissance (€1M equity) and Bpifrance (€500k French Tech Seed debt), founded by Amaury Dupas. The company develops Ze One, an electric conversion kit that attaches to any existing manual wheelchair and turns it into an all-terrain electric wheelchair. The product appeared at CES 2026. The core insight is additive: Ze One avoids the prescription and reimbursement process for a replacement powered chair by improving the one already prescribed. Capital funds industrialisation and commercialisation; CE marking under EU MDR is the gate before commercial launch, with no timeline disclosed.

Next edition: Tuesday 29 September 2026.